MF Diagnosis and Prognosis

These tools are designed to help evaluate a patient for myelofibrosis (MF). For patients who have been diagnosed with MF, the tools can help estimate prognosis based on validated models.

Estimating Prognosis in Myelofibrosis (MF)

Prognostic Criteria

Determining prognosis can be challenging because myelofibrosis has a very heterogeneous presentation. As the clinical understanding of myelofibrosis has evolved, a variety of prognostic systems have been developed.1

All of the systems utilize a group of risk factors to assign risk level (low, intermediate, or high) and to determine expected median life expectancy based on risk level, which may be useful in counseling patients with MF and deciding on therapeutic approach.1-3

The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) developed the International Prognostic Scoring System (IPSS) and the Dynamic International Prognostic Scoring System (DIPSS).1,2

Both IPSS and DIPSS use the same risk factors when estimating prognosis, but they differ in how the risk factors are weighted.1,2 IPSS is used only at time of diagnosis, while DIPSS may be used throughout the disease course.1,2

DIPSS Plus is based on DIPSS and includes additional risk factors, specifically karyotype, transfusion dependency, and platelet count less than 100 × 109/L.3

Indicate which prognostic system you would like to use and check the criteria corresponding to the patient’s clinical presentation.

IPSS
IPSS is used to assess prognosis at the time of diagnosis1
DIPSS
DIPSS is used to assess prognosis any time during the disease course2
DIPSS Plus
DIPSS Plus is a refined scoring system based on DIPSS and 3 additional factors3

Patient History

Age 65 or above

Constitutional symptoms 

Lab Results

Hemoglobin level <10 g/dL

Leukocyte count >25 × 109/L

Circulating blast cells ≥1%

Patient History

Age 65 or above

Constitutional symptoms 

Lab Results

Hemoglobin level <10 g/dL

Leukocyte count >25 × 109/L

Circulating blast cells ≥1%

Patient History

Age 65 or above

Constitutional symptoms 

Lab Results

Hemoglobin level <10 g/dL

Leukocyte count >25 × 109/L

Circulating blast cells ≥1%

Platelets <100 × 109/L

KARYOTYPE

Unfavorable karyotype 

TRANSFUSION NEED

Red cell transfusion dependent

References

1. Cervantes F, Dupriez B, Pereira A, et al. Blood. 2009;113:2895-2901. 2. Passamonti F, Cervantes F, Vannucchi AM, et al. Blood. 2010;115:1703-1708. 3. Gangat N, Caramazza D, Vaidya R, et al. J Clin Oncol. 2011;29:392-397.